Her-2 over-expression was statistically significant associated with loss of HmR positive immuno-staining (P < 0.0001), grade III breast cancer (P < 0.0001), advanced lymph node status (P = 0.0039), and patient <50 years of age (P = 0.0108) (Table 5). Here, ERBB2 is linked to breast carcinoma.